» Portfolio News

16.05.17

NOXXON Pharma kündigt Zusammenarbeit mit Nationalem Zentrum für Tumorerkrankungen in Heidelberg bei NOX-A12/Keytruda® Phase 1/2 Kombinationsstudie an

Weiterlesen...

02.05.17

NOXXON PHARMA secures a private placement of €1 million and additional financing of up to €10 million through convertible notes with share subscritpion warrants attached to finance further clinical development of NOX-A12

Weiterlesen...

30.04.17

NOXXON PHARMA N.V. berichtet über Finanzergebnisse 2016 und informiert über fortgeschrittene Verhandlung über eine Wandelanleihe

Weiterlesen...

10.02.17

NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO

Weiterlesen...

04.01.17

NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

Weiterlesen...

04.01.17 - NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion


NOXXON continues transition to clincal oncology company

 


Berlin, Germany, January 04, 2017 - NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion.

 

 

NOXXON has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer® technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.

 

 

“This agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed.” commented Aram Mangasarian, CEO of NOXXON.